<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82897">
  <stage>Registered</stage>
  <submitdate>12/06/2008</submitdate>
  <approvaldate>9/07/2008</approvaldate>
  <actrnumber>ACTRN12608000318381</actrnumber>
  <trial_identification>
    <studytitle>Double Blind Randomised Crossover Trial of Temazepam in Mild to Moderate Obstructive Sleep Apnea</studytitle>
    <scientifictitle>Efficacy of Teazepam in reducing Apnea Hypopnea Index as measured by standard overnight polysomnography in mild to moderate obstructive sleep apnea.</scientifictitle>
    <utrn />
    <trialacronym>TEMOSA</trialacronym>
    <secondaryid>SSWAHS Ethics Review Committee (Protocol No: X08-0079)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnea (OSA)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>10 mg Temazepam over 1 night only administered orally. As this is a crossover study, there will be a 2 week washout period.</interventions>
    <comparator>Placebo (sugar pill). 
Administered orally over 1 night only</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Apnea Hypopnea Index (AHI)</outcome>
      <timepoint>Measured by standard overnight polysomnography (PSG) for both nights (i.e. the night temazepam is administered and the night placebo is administered.)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between reduced AHI and hypoxic ventilatory response (HVR) and hypercapnic ventilatory response (HVCR).</outcome>
      <timepoint>Ventilatory responses taken at all 3 visits (baseline, study medication visit, and placebo visit.)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must be male, aged 18 to 70, Body Mass Index (BMI) &lt; 35, diagnosed obstructive sleep apnea by overnight polysomnography (Apnea-Hypopnea Index =5, = 30), and refuse or cannot tolerate a continuous positive airway pressure device and/or a mandibular advancement splint.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded if they are suffering from any uncontrolled concurrent medical or psychiatric illness, if they are currently taking any medications that are known to affect sleep or that may cause a drug interaction with Temazepam, if they have medical conditions that would contraindicate administration of Temazepam or if they have irregular sleep patterns, such as shift-workers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After written consent, patients will be enrolled in a randomised order placebo-controlled crossover double blind study. After the baseline visit patients will be randomly assigned, by equal chance, either 10mg Temazepam or placebo. Allocation is concealed via central randomization by computer.</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software (i.e., computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>22</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>431 Glebe Point Road
GLEBE NSW 2037</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Woolcock Institute of Medical Research</fundingname>
      <fundingaddress>431 Glebe Point Road
GLEBE NSW 2037</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The efficacy of Temazepam on sleep disordered breathing in untreated patients with mild to moderate OSA as measured by the Apnea Hypopnea Index (AHI) via standard overnight polysomnography (PSG). The effect of temazepam on OSA will be correlated with awake HVR and HCVR. The hypothesis is that Temazepam reduction of OSA will be correlated with the baseline HVR and HCVR.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Services (SSWAHS) Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>c/- Research Development Office
Level 8, Building 14
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate>27/05/2008</ethicapprovaldate>
      <hrec>08/RPAH/130</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Ron Grunstein</name>
      <address>Woolcock Institute of Medical Research,PO Box M77, Missenden Rd, Camperdown, NSW, 2050</address>
      <phone>+61 2 9515 8630</phone>
      <fax>+61 2 9114 0014</fax>
      <email>swilliams@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Nargis Noori</name>
      <address>Woolcock Institute of Medical Research,PO Box M77, Missenden Rd, Camperdown, NSW, 2050</address>
      <phone>+61 2 9114 0498</phone>
      <fax>+61 2 9114 0014</fax>
      <email>nnoo3880@mail.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Valennia Tan</name>
      <address>431 Glebe Point Road 
GLEBE NSW 2037</address>
      <phone>+61 2 9114 0353</phone>
      <fax>+61 2 9114 0013</fax>
      <email>velse@woolcock.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>